MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Yttrium-90 Radioembolization
Recent advances in hepatic embolotherapy.
By David M. Liu, MD, FRCP(C); David N. Cade, MD; Jesse Knight, MD; Rodney Raabe, MD; Stephen Kee, MD; Andrew Kennedy, MD, FACRO; and Riad Salem, MD, FSIR, MBA
ABK Biomedical Gains IDE Approval for Pivotal Study of Eye90 Microspheres to Treat Hepatocellular Carcinoma
May 30, 2023—ABK Biomedical, Inc. announced it has received Investigational Device Exemption approval from the FDA to commence a multicenter pivotal clinical study in the United States for the company’s imageable Eye90 microspheres yttrium-90 (Y90) radioembolization therapy.
Embolization Therapies
By Barry T. Katzen, MD, Chief Medical Editor
ROUTE90 Pivotal Study of ABK’s Eye90 Microspheres for Primary Liver Cancer Completes Enrollment
February 25, 2026—ABK Biomedical, Inc. announced the completion of patient enrollment in the ROUTE90 pivotal study evaluating the company’s Eye90 microspheres, an yttrium-90 (Y90) transarterial radioembolization (TARE) device for the treatment of hepatocellular carcinoma (HCC).
NCCN Guidelines Recommend SIR-Spheres Y-90 Resin Microspheres to Treat Metastatic Colorectal Cancer
December 12, 2016—Sirtex Medical Limited announced that the company's SIR-Spheres yttrium-90 (Y-90) resin microspheres have been included as a category 2A recommended treatment in the latest National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology for colon cancer and rectal cancer.
